G lucagon-like peptide-1 receptor agonists, aka GLP-1 agonists, such as semaglutide -- better known as Ozempic -- have ...

Semaglutide is a glucagon-like peptide ... and death from cardiovascular causes in patients with T2D and chronic kidney disease (CKD). 10 Semaglutide is commercially available under three separate ...

With semaglutide shortages in the rearview, Novo Nordisk is doubling down on marketing efforts for its GLP-1 drugs.

Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease (CKD ... stopped a phase 3b trial of semaglutide, the active ingredient ...

Some studies sponsored by Novo Nordisk suggest that semaglutide may actually help reduce the risk of kidney disease over the ... including worsening chronic kidney failure, especially if ...

Ozempic and similar GLP-1 weight-loss medications are designed to be a lifelong treatment. But a new study finds the majority ...

GLP-1 receptor agonists were initially approved for glycaemic control in type 2 diabetes and, subsequently, for bodyweight loss in obesity. Following large-scale trials demonstrating that some GLP-1 ...

NovoCare Pharmacy will provide all dose strengths of Wegovy at a reduced cost of $499 per month for cash-paying patients ...

New data show that GLP1-RA meds like semaglutide can help slow the progression of chronic kidney disease The meds outperformed another class of drugs called DPP4is Researchers believe the findings ...

Novo Nordisk launched "My Ozempic® Era" today, a national campaign which spotlights the longstanding Ozempic® patient ...